Standard Versus Hypofractionated Low-Dose Total Skin Electron Therapy for Cutaneous T-Cell Lymphoma: A Single-Institution Retrospective Analysis
Practical Radiation Oncology · 2026-11 · 16 (6) · e461-e472
DOI: 10.1016/j.prro.2026.04.006 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Practical Radiation Oncology, 2026-11. Verfasst von Jonathan Baron und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: baronjo@pennmedicine.upenn.edu. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Cutaneous, Skin Neoplasms, Radiation Dose Hypofractionation, Electrons. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Daiichi-Sankyo, Kyowa Kirin.
Abstract (Originalsprache)
PURPOSE: Low-dose total skin electron therapy (TSET) is an established treatment for diffuse cutaneous T-cell lymphoma. Although traditionally delivered using standard fractionation (STD-fx) schedules, hypofractionated (H-fx) regimens offer a practical, time-efficient alternative; however, comparative data remain limited. This study evaluated clinical responses, toxicity, and hematologic effects of H-fx versus STD-fx low-dose TSET. METHODS AND MATERIALS: We retrospectively analyzed 121 courses of low-dose TSET (12 Gy total) delivered to 111 patients with cutaneous T-cell lymphoma from 2015 to 2023. STD-fx was defined as 12 Gy in 6 fractions; H-fx included regimens of 12 Gy in 3 or 4 fractions. Acute toxicities were graded per the Common Terminology Criteria for Adverse Events v5.0 and categorized as "new or worsened" from baseline. Hematologic toxicity was assessed through serial complete blood counts. Overall survival and progression-free survival were measured from TSET completion to event or last follow-up; survival comparisons between regimens were exploratory. RESULTS: Of 121 TSET courses, 104 (86%) were STD-fx and 17 (14%) were H-fx. Median follow-up was 21 months overall and was shorter in H-fx (8 vs 22 months; P < .01). Eastern Cooperative Oncology Group 2 to 4 status was more frequent in H-fx (35% vs 13%; P = .03). Overall response rate (complete response + partial response) was 94% in both groups. At 24 months, overall survival was 87% for STD-fx versus 66.7% for H-fx (P = .13), and progression-free survival was 19% versus 17%, respectively (P = .59). New or worsened acute toxicities were common (98.1% vs 94.1%; P = .37) but mostly low-grade, with no grade 4 events. Rates of dermatitis were similar in STD-fx and H-fx groups (76.9% vs 76.5%), including high-grade events (12.5% vs 23.5%; P = .26). Cytopenias were prevalent at baseline and remained similar posttreatment, with no significant differences between regimens. CONCLUSIONS: H-fx low-dose TSET was feasible and demonstrated similar short-term response, acute toxicity, and hematologic effects as STD-fx, although long-term and comparative inferences are limited by the small H-fx cohort and short follow-up duration. In appropriately selected patients, abbreviated TSET regimens may be considered when shorter treatment courses are clinically indicated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: baronjo@pennmedicine.upenn.edu.
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania.
- Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania.
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
- Center for Clinical Epidemiology & Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania.
- Department of Hematology/Oncology, University of Pennsylvania, Philadelphia, Pennsylvania.
Förderung
- Daiichi-Sankyo
- Kyowa Kirin
Zitieren
APA
Baron, J., Chelius, M., Cohen, L., Perez, C. C., Riina, M., Ramesh, S., Tierney, A., Elghawy, O., Hossain, N. M., Rook, A., Villasenor-Park, J., Samimi, S., Kim, E., Hubbeling, H., Plastaras, J. P., Barta, S. K., & LaRiviere, M. (2026). Standard Versus Hypofractionated Low-Dose Total Skin Electron Therapy for Cutaneous T-Cell Lymphoma: A Single-Institution Retrospective Analysis. Practical Radiation Oncology, 16(6), e461-e472. https://doi.org/10.1016/j.prro.2026.04.006
Vancouver
Baron J, Chelius M, Cohen L, Perez CC, Riina M, Ramesh S, et al. Standard Versus Hypofractionated Low-Dose Total Skin Electron Therapy for Cutaneous T-Cell Lymphoma: A Single-Institution Retrospective Analysis. Practical Radiation Oncology. 2026;16(6):e461-e472. doi:10.1016/j.prro.2026.04.006
BibTeX
@article{Baron2026,
author = {Baron, Jonathan and Chelius, Monica and Cohen, Leah and Perez, Carlos Chavez and Riina, Matthew and Ramesh, Sidharth and Tierney, Ann and Elghawy, Omar and Hossain, Nasheed Mohammad and Rook, Alain and Villasenor-Park, Jennifer and Samimi, Sara and Kim, Ellen and Hubbeling, Harper and Plastaras, John P and Barta, Stefan K and LaRiviere, Michael},
title = {Standard Versus Hypofractionated Low-Dose Total Skin Electron Therapy for Cutaneous T-Cell Lymphoma: A Single-Institution Retrospective Analysis},
journal = {Practical Radiation Oncology},
year = {2026},
volume = {16},
number = {6},
pages = {e461--e472},
doi = {10.1016/j.prro.2026.04.006}
}
EUVIMED